title: Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.
abstract: To improve immune responses to influenza vaccine, a trivalent inactivated vaccine containing 60 microg of the HA of each component (A/H3N2, A/H1N1, B) was compared to a licensed vaccine containing 15 microg of the HA of each. More local and systemic reactions were reported by subjects given the high dosage but only local pain and myalgias were significantly increased. The high dosage vaccine induced a higher frequency of serum antibody increases (> or =4-fold) in both hemagglutination-inhibiting (HAI) and neutralization tests for all three vaccine viruses in the total group as well as subjects vaccinated and those not vaccinated the previous year. Mean titers of antibody attained, the magnitude of antibody increases and the frequencies of persons with final HAI antibody titers > or =1:32, > or =1:64, and > or =1:128 were all greater for the high dosage group in both serologic tests, for all groups, and for all vaccine viruses. These increased immune responses should provide increased protection against influenza in the elderly.
authors.affiliation: Baylor College of Medicine, One Baylor Plaza, MS: BCM280, Houston, TX 77030, United States. ikirk@bcm.edu
authors.forename: Robert B
authors.initials: RB
authors.lastname: Couch
authors.forename: Patricia
authors.initials: P
authors.lastname: Winokur
authors.forename: Rebecca
authors.initials: R
authors.lastname: Brady
authors.forename: Robert
authors.initials: R
authors.lastname: Belshe
authors.forename: Wilbur H
authors.initials: WH
authors.lastname: Chen
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Cate
authors.forename: Bryndis
authors.initials: B
authors.lastname: Sigurdardottir
authors.forename: Amy
authors.initials: A
authors.lastname: Hoeper
authors.forename: Irene L
authors.initials: IL
authors.lastname: Graham
authors.forename: Robert
authors.initials: R
authors.lastname: Edelman
authors.forename: Fenhua
authors.initials: F
authors.lastname: He
authors.forename: Diane
authors.initials: D
authors.lastname: Nino
authors.forename: Jose
authors.initials: J
authors.lastname: Capellan
authors.forename: Frederick L
authors.initials: FL
authors.lastname: Ruben
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006385:Hemagglutination Inhibition Tests; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000276:immunology; D008297:Male
chemical_list: D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines